Berg et al. documented an OR of 3.4 for local recurrence for patients with loss of RUNX3 expression in a small series comprising 64 stage II–III colon cancer patients evaluated for MSI, CIMP, and copy number variation [43]. Here, RUNX3 is linked to colonic neoplasm.